MiCo BioMed Co., Ltd. (KOSDAQ: 214610)
South Korea
· Delayed Price · Currency is KRW 1,467.00
+27.00 (1.88%)
Dec 20, 2024, 9:00 AM KST
MiCo BioMed Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Other Revenue | 0 | 0 | - | -0 | - | - |
| Revenue | 8,303 | 5,367 | 16,111 | 30,302 | 45,672 | 4,098 |
| Revenue Growth (YoY) | 61.39% | -66.69% | -46.83% | -33.65% | 1014.47% | - |
| Cost of Revenue | 16,753 | 12,339 | 16,690 | 15,599 | 24,808 | 4,719 |
| Gross Profit | -8,450 | -6,971 | -578.73 | 14,704 | 20,864 | -621.09 |
| Selling, General & Admin | 11,287 | 6,904 | 11,875 | 12,449 | 10,072 | 4,794 |
| Research & Development | 4,203 | 4,036 | 7,454 | 7,831 | 6,150 | 5,114 |
| Other Operating Expenses | 359.23 | 191.61 | 279.94 | 196.69 | 168.1 | 71.6 |
| Operating Expenses | 17,464 | 13,012 | 25,343 | 25,562 | 17,399 | 11,126 |
| Operating Income | -25,914 | -19,983 | -25,922 | -10,859 | 3,466 | -11,747 |
| Interest Expense | -1,760 | -3,175 | -2,425 | -574.75 | -694.21 | -995.24 |
| Interest & Investment Income | 462.43 | 426.08 | 310.91 | 82.3 | 48.43 | 64.36 |
| Currency Exchange Gain (Loss) | 45.97 | 5.29 | 494.91 | 925.55 | -866.05 | 47.96 |
| Other Non Operating Income (Expenses) | 277.56 | -361.25 | -2,357 | -172.32 | -7,694 | 19.52 |
| EBT Excluding Unusual Items | -26,888 | -23,088 | -29,898 | -10,598 | -5,741 | -12,610 |
| Gain (Loss) on Sale of Investments | -1,707 | -3,802 | -7,764 | - | - | - |
| Gain (Loss) on Sale of Assets | 3.36 | 2,063 | -192.28 | -0.55 | - | 12.98 |
| Asset Writedown | -749.66 | -739.18 | -1,078 | - | -48.08 | -2,058 |
| Other Unusual Items | -744.51 | -242.39 | - | - | - | - |
| Pretax Income | -30,086 | -25,808 | -38,932 | -10,598 | -5,789 | -14,655 |
| Income Tax Expense | -12.97 | -12.97 | -12.86 | -12.97 | -12.97 | -16.21 |
| Earnings From Continuing Operations | -30,073 | -25,795 | -38,919 | -10,585 | -5,776 | -14,639 |
| Minority Interest in Earnings | 65.48 | 20.62 | 26.65 | 10.18 | 0.07 | 7.45 |
| Net Income | -30,008 | -25,774 | -38,893 | -10,575 | -5,776 | -14,632 |
| Net Income to Common | -30,008 | -25,774 | -38,893 | -10,575 | -5,776 | -14,632 |
| Shares Outstanding (Basic) | 41 | 25 | 22 | 22 | 17 | 14 |
| Shares Outstanding (Diluted) | 41 | 25 | 22 | 22 | 17 | 14 |
| Shares Change (YoY) | 86.40% | 12.70% | 0.19% | 25.24% | 22.97% | - |
| EPS (Basic) | -732.92 | -1041.54 | -1771.26 | -482.52 | -330.05 | -1028.15 |
| EPS (Diluted) | -732.92 | -1042.00 | -1771.26 | -482.52 | -330.05 | -1028.35 |
| Free Cash Flow | -16,077 | -11,744 | -15,631 | -11,441 | -24,440 | -11,773 |
| Free Cash Flow Per Share | -392.68 | -474.58 | -711.86 | -522.03 | -1396.60 | -827.27 |
| Gross Margin | -101.77% | -129.88% | -3.59% | 48.52% | 45.68% | -15.16% |
| Operating Margin | -312.10% | -372.30% | -160.89% | -35.83% | 7.59% | -286.65% |
| Profit Margin | -361.41% | -480.20% | -241.40% | -34.90% | -12.65% | -357.04% |
| Free Cash Flow Margin | -193.63% | -218.81% | -97.02% | -37.76% | -53.51% | -287.28% |
| EBITDA | -23,793 | -17,673 | -23,075 | -8,419 | 5,242 | -10,036 |
| EBITDA Margin | -286.55% | - | -143.22% | -27.78% | 11.48% | -244.91% |
| D&A For EBITDA | 2,122 | 2,310 | 2,847 | 2,439 | 1,776 | 1,711 |
| EBIT | -25,914 | -19,983 | -25,922 | -10,859 | 3,466 | -11,747 |
| EBIT Margin | - | - | -160.89% | -35.83% | 7.59% | -286.65% |
| Advertising Expenses | - | 557.28 | 1,002 | 2,891 | 1,030 | 547.13 |
Source: S&P Capital IQ. Standard template. Financial Sources.